David Fedor1, W Rainey Johnson, Sunil Singhal. 1. Thoracic Surgery Research Laboratory, Department of Surgery, Perelman School of Medicine, Philadelphia, PA, USA. dfedor@mail.med.upenn.edu
Abstract
PURPOSE: To date, few large-scale original studies have focused specifically on local recurrence following curative lung cancer surgery. This review seeks to consolidate and analyze data from these studies regarding local recurrence incidence, risk factors, salvage treatments, and outcomes to increase awareness in the Oncology community and to spark new research in this area. METHODS: PubMed literature was searched for large-scale cohort studies involving recurrence following lung cancer surgery. Studies with a primary focus on local recurrence and studies that examined overall recurrence but provided relevant numerical data on local recurrence were included. Each chosen study's methods were critically analyzed to reconcile as best as possible large differences in reported results across the studies. RESULTS: Up to 24% of patients recur locally following lung cancer surgery. Risk of local recurrence increases with the stage of the primary cancer, but even stage I patients experience local recurrence up to 19% of the time. Overall survival time following local recurrence varies widely across studies, from 7 to 26 months, and may be related to frequency of follow-up visits. Salvage therapy appears to increase survival time. However, estimates of this increase vary widely, and measurements of benefits of the various salvage options are confounded by lack of control of subjects' condition at the time of salvage therapy administration. CONCLUSIONS: Local recurrence following lung cancer surgery is a significant problem warranting additional research. At present, data on this topic is scarce. We recommend initiation of additional large-scale studies to clearly define the parameters of local recurrence in order to provide useful guidance to clinicians.
PURPOSE: To date, few large-scale original studies have focused specifically on local recurrence following curative lung cancer surgery. This review seeks to consolidate and analyze data from these studies regarding local recurrence incidence, risk factors, salvage treatments, and outcomes to increase awareness in the Oncology community and to spark new research in this area. METHODS: PubMed literature was searched for large-scale cohort studies involving recurrence following lung cancer surgery. Studies with a primary focus on local recurrence and studies that examined overall recurrence but provided relevant numerical data on local recurrence were included. Each chosen study's methods were critically analyzed to reconcile as best as possible large differences in reported results across the studies. RESULTS: Up to 24% of patients recur locally following lung cancer surgery. Risk of local recurrence increases with the stage of the primary cancer, but even stage I patients experience local recurrence up to 19% of the time. Overall survival time following local recurrence varies widely across studies, from 7 to 26 months, and may be related to frequency of follow-up visits. Salvage therapy appears to increase survival time. However, estimates of this increase vary widely, and measurements of benefits of the various salvage options are confounded by lack of control of subjects' condition at the time of salvage therapy administration. CONCLUSIONS: Local recurrence following lung cancer surgery is a significant problem warranting additional research. At present, data on this topic is scarce. We recommend initiation of additional large-scale studies to clearly define the parameters of local recurrence in order to provide useful guidance to clinicians.
Authors: Mert Saynak; Nirmal K Veeramachaneni; Jessica L Hubbs; Jiho Nam; Bahjat F Qaqish; Janet E Bailey; Wonil Chung; Lawrence B Marks Journal: Lung Cancer Date: 2010-07-07 Impact factor: 5.705
Authors: W J Curran; S H Herbert; P M Stafford; H M Sandler; S A Rosenthal; W G McKenna; E Hughes; M J Dougherty; S Keller Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Brendon M Stiles; Elliot L Servais; Paul C Lee; Jeffrey L Port; Subroto Paul; Nasser K Altorki Journal: J Thorac Cardiovasc Surg Date: 2009-01 Impact factor: 5.209
Authors: Min Suk Choi; Joon Suk Park; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Kwhanmien Kim Journal: Korean J Thorac Cardiovasc Surg Date: 2011-04-14
Authors: Stephen Gowing; Laura Baker; Alexandre Tran; Zach Zhang; Hilalion Ahn; Jelena Ivanovic; Caitlin Anstee; Emma Grigor; Sebastien Gilbert; Donna E Maziak; Farid Shamji; Sudhir Sundaresan; Patrick James Villeneuve; Andrew J E Seely Journal: Lung Date: 2020-10-09 Impact factor: 2.584
Authors: Dario Consonni; Mariaelena Pierobon; Mitchell H Gail; Maurizia Rubagotti; Melissa Rotunno; Alisa Goldstein; Lynn Goldin; Jay Lubin; Sholom Wacholder; Neil E Caporaso; Pier Alberto Bertazzi; Margaret A Tucker; Angela C Pesatori; Maria Teresa Landi Journal: J Natl Cancer Inst Date: 2015-03-23 Impact factor: 13.506
Authors: Jane J Keating; Olugbenga T Okusanya; Elizabeth De Jesus; Ryan Judy; Jack Jiang; Charuhas Deshpande; Shuming Nie; Philip Low; Sunil Singhal Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Jack X Jiang; Jane J Keating; Elizabeth M De Jesus; Ryan P Judy; Brian Madajewski; Ollin Venegas; Olugbenga T Okusanya; Sunil Singhal Journal: Am J Nucl Med Mol Imaging Date: 2015-06-15
Authors: Michelle C Salazar; Joshua E Rosen; Zuoheng Wang; Brian N Arnold; Daniel C Thomas; Roy S Herbst; Anthony W Kim; Frank C Detterbeck; Justin D Blasberg; Daniel J Boffa Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777